Rituximab (Rituxan, Ruxience, Truxima, Riabni)_Non-oncology

Rituximab is covered for specified non‑oncology FDA‑approved indications (moderate–severe RA, GPA, MPA, pemphigus vulgaris) and certain compendial off‑label uses (ITP, MS, NMO spectrum disorder, SLE, GVHD); oncology indications are excluded. Coverage requires meeting indication‑specific criteria including prior therapy trials (e.g., DMARDs/biologics for RA; other agents for MS, ITP, SLE, GVHD), specialist prescription/consultation, restrictions on concurrent biologic/targeted agents, minimum intervals between courses (typically ≥16 weeks or ≥6 months where specified), documented response for reauthorization, and adherence to the policy dosing/timing.

"Moderately to severely active rheumatoid arthritis (FDA-approved non-oncology indication)"

Sign up to see full coverage criteria, indications, and limitations.